

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Zeldis	Confirmation No.:	2389
Serial No.:	10/693,722	Art Unit:	1623
Filed:	October 23, 2003	Examiner:	OLSON, Eric
For:	METHODS FOR TREATMENT OF COMPLEX REGIONAL PAIN SYNDROME USING (+)-{2-[1-(3- ETHOXY-4-METHOXYPHENYL)- 2-METHYLSULFONYLETHYL]-4- ACETYLAMINOISOINDOLINE-1,3- DIONE}	Attorney Docket No: (CAM:	9516-078-999 501872-999077)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.56 AND §1.97

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Applicants hereby direct the Examiner's attention to references **A123** and **B01** listed on the attached form PTO 1449 entitled "List of References Cited by Applicant." The references were cited in the Office Action dated June 26, 2008 in the corresponding European patent application, which is listed on the attached form PTO 1449 as reference **C05**. Copies of reference B01 and C05 are submitted herewith.

Identification of the listed references is not to be construed an admission of Applicant or Attorneys for Applicant that such references are available as "prior art" against the subject application. Applicant respectfully requests that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R. §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application. However, in accordance with 37 C.F.R. §1.97(e)(1), it is certified that each reference contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information disclosure statement. Therefore, no fee is believed to be due with this submission. However, pursuant to 37 C.F.R. §1.136 (a)(3), the Commissioner is authorized to charge all required fees, fees under 37 C.F.R. § 1.17 and all required extension of time fees, or credit any overpayment, to Jones Day Deposit Account No. **503013**.

Respectfully submitted,

Date: September 18, 2008



Mark D. Kafka Reg. No. 59,569
For: Anthony M. Insogna Reg. No. 35,203
JONES DAY
222 East 41st Street
New York, NY 10017
Tel. (212) 326-3778